Invited Commentary
May 23, 2011

Inhaled Anticholinergics for Chronic Obstructive Pulmonary DiseaseComment on “Inhaled Anticholinergic Drug Therapy and the Risk of Acute Urinary Retention in Chronic Obstructive Pulmonary Disease”

Author Affiliations

Author Affiliations: Department of Medicine, The John Hopkins University School of Medicine, and Department of Epidemiology and International Health, Bloomberg School of Public Health, Baltimore, Maryland (Dr Singh); and Division of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina (Dr Furberg).


Copyright 2011 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2011

Arch Intern Med. 2011;171(10):920-922. doi:10.1001/archinternmed.2011.171

Chronic obstructive pulmonary disease is the third leading cause of death in the United States and is one of the only major diseases for which the mortality rate is rising.1 Apart from respiratory causes, the major causes of death among patients with COPD include cardiovascular death and infectious complications, such as pneumonia. The SAAC ipratropium and LAAC tiotropium and the long-acting β2-agonist inhaled corticosteroid combination inhalers are approved for use in the United States. The benefits of IACs include their ability to provide symptomatic relief, to reduce exacerbations (by approximately 13%-25%), and to modestly improve forced expiratory volume in the first second of expiration. However, none of the marketed agents slow the progressive decline of the latter measure over time or improve survival. Therefore, information on serious adverse effects associated with IACs can potentially alter their benefit-harm assessment.

First Page Preview View Large
First page PDF preview
First page PDF preview